While BioNTech SE ADR has underperformed by -0.52%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BNTX rose by 2.58%, with highs and lows ranging from $131.49 to $76.53, whereas the simple moving average fell by -8.97% in the last 200 days.
On March 13, 2025, Citigroup started tracking BioNTech SE ADR (NASDAQ: BNTX) recommending Buy. A report published by Truist on January 10, 2025, Initiated its previous ‘Buy’ rating for BNTX. Wells Fargo also rated BNTX shares as ‘Overweight’, setting a target price of $170 on the company’s shares in an initiating report dated December 11, 2024. Evercore ISI November 19, 2024d its ‘In-line’ rating to ‘Outperform’ for BNTX, as published in its report on November 19, 2024. Berenberg’s report from November 19, 2024 suggests a price prediction of $130 for BNTX shares, giving the stock a ‘Buy’ rating. Goldman also rated the stock as ‘Buy’.
Analysis of BioNTech SE ADR (BNTX)
Further, the quarter-over-quarter decrease in sales is -20.19%, showing a negative trend in the upcoming months.
In order to gain a clear picture of BioNTech SE ADR’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -3.38% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.34, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 778.02K can be a very valuable indicator of volatility for BNTX stock. On a monthly basis, the volatility of the stock is set at 4.07%, whereas on a weekly basis, it is put at 4.14%, with a loss of -0.86% over the past seven days. Furthermore, long-term investors anticipate a median target price of $137.34, showing growth from the present price of $95.40, which can serve as yet another indication of whether BNTX is worth investing in or should be passed over.
How Do You Analyze BioNTech SE ADR Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.56%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 20.66% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BNTX shares are owned by institutional investors to the tune of 20.66% at present.
